Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.81 |
| ▸ | TEC | P42680 | 5/20 | 0.61 |
| ▸ | TXK | P42681 | 4/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.58 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.58 |
| ▸ | ITK | Q08881 | 2/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | BLK | P51451 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16755398 | 0.93 | EGFR (0.79) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755401 | 0.92 | EGFR (0.75) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755403 | 0.92 | EGFR (0.78) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755455 | 0.90 | EGFR (0.75) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755416 | 0.90 | EGFR (1.00) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755437 | 0.89 | MAP3K7 (0.76) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16755420 | 0.87 | EGFR (0.70) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16767967 | 0.87 | EGFR (0.61) | EGFRTECTXKMAP3K7IRAK1 | |
| SCHEMBL16767961 | 0.85 | MAP3K7 (0.63) | EGFRTECMAP3K7IRAK1IRAK4 | |
| SCHEMBL16755456 | 0.82 | EGFR (0.75) | EGFRTECTXKERBB2BLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885TEC 466/4885TXK 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.